Following the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has ...

Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 - LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics ...

20 x 17 cm. (7.9 x 6.7 in.) ...

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced its financial results for ...

After hours: 15 November at 17:05 GMT-5 ...

ESSEX, Conn.--(BUSINESS WIRE)--#IBD--Thetis Pharmaceuticals, LLC (“Thetis”), a pharmaceutical company developing an oral, small molecule Resolvin E1 (RvE1) drug targeting the BLT1 receptor to treat ...